How I manage priapism in chronic myeloid leukaemia patients

Rodgers, R., Latif, Z. and Copland, M. (2012) How I manage priapism in chronic myeloid leukaemia patients. British Journal of Haematology, 158(2), pp. 155-164. (doi: 10.1111/j.1365-2141.2012.09151.x)

Full text not currently available from Enlighten.


Priapism is a rare presenting feature of chronic myeloid leukaemia (CML). It is a urological emergency requiring urgent treatment to prevent long-term complications, in particular erectile dysfunction. In males with CML, ischaemic priapism is believed to result from hyperleucocytosis and associated leucostasis or hyperviscosity, and is seen in patients presenting with a high white cell count. Increasingly, a combined modality approach is being used to treat CML patients presenting with priapism. This includes systemic therapy with chemotherapy (hydroxycarbamide or tyrosine kinase inhibitors) and therapeutic leukapheresis to reduce the white cell count as well as local intracavernous therapy. This review will examine the literature and discuss the presenting features, investigations and management of priapism in CML.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Copland, Professor Mhairi
Authors: Rodgers, R., Latif, Z., and Copland, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:British Journal of Haematology
Publisher:Blackwell Publishing
Published Online:10 May 2012

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
506531An investigation of the control of cell division and quiescence in leukaemic versus normal haemopoietic stem and progenitor cellsMhairi CoplandScottish Executive Health DepartmentSEHHD-CSORI CANCER SCIENCES